Sector Expert: William Plovanic

Canaccord Genuity

Image: William Plovanic

William Plovanic joined Canaccord in 2007 as a managing director, medical technology equity research analyst. He has been a publishing sellside analyst with coverage of medical devices for over 20 years. Plovanic's areas of coverage include orthopedics, diabetes, obesity, neuro-technologies, dialysis, aesthetics and general surgery. In 2009, Plovanic was ranked as the #2 Earnings Estimator for Health Care Equipment & Supplies by Starmine. In 2003 and 2004, he was selected as a Wall Street Journal "All Star" Analyst in the medical device sector, and in 2002 was named the #1 ranked analyst by Starmine for stock picking and performance in the medical technology sector. Plovanic is a frequent presenter at medical and industry meetings. Prior to Canaccord, Plovanic was a managing director and senior research analyst at First Albany (now Gleacher & Company). Previously, he worked at PMG Capital covering medical devices and products. Plovanic also worked as director of research for the Capital Markets Division of LaSalle St. Securities Inc., where he focused on the small-cap healthcare, technology and biotechnology industries. He graduated from Bradley University with a bachelor's degree in finance, and is a Chartered Financial Analyst.

Recent Interviews

Medtech Shifts from High Gear into Overdrive: Canaccord’s William Plovanic (8/19/14)

Rapid growth in the medical device industry and changes in the regulatory environment have propelled valuations in the medtech sector to the high end of the range. But new technologies create new investment opportunities. In this interview with The Life Sciences Report, William Plovanic of Canaccord Genuity highlights investment opportunities in medtech companies with innovative products targeting high-impact areas such as obesity, diabetes and wound care.

What Will Boost Medtech Stocks? Look for a Better Mousetrap, Says William Plovanic (2/21/13)

Growth in the medical technology industry may have slowed, and governmental hurdles may make the forecast gloomy, but value plays await the investor who understands how innovation can drive company stock prices upward. In this interview with The Life Sciences Report, William Plovanic, analyst and managing director with Canaccord Genuity, talks about his top names in medtech and why he believes investors need to take advantage of the slowdown now. He also ruminates on the potential effects of Obamacare's impending implementation.

Special Report from the ADA: William Plovanic Identifies Companies with Promising Diabetes Solutions, Prospects (6/21/12)

Every year, top researchers and physicians meet at the American Diabetes Association Scientific Sessions. This year, Canaccord Genuity Analyst and Managing Director William Plovanic reported back on promising developments and what they could mean for the companies behind them. In this interview with The Life Sciences Report, he explains why he is so positive on the space in general and about certain companies in particular.

Recent Quotes

"We are raising our price target for MDXG."

— William Plovanic, Canaccord Genuity (10/15/14)
more >

"MDXG provides better, faster and cheaper technology compared to current wound-care therapies."

— William Plovanic, Canaccord Genuity (8/19/14)
more >

"MDXG has quickly become a top pick in the advanced wound care dermal substitute segment."

— William Plovanic, Canaccord Genuity (7/29/14)
more >

"We believe EXAC stock is undervalued relative to its peers."

— William Plovanic, Canaccord Genuity (10/31/12)
more >

"We reiterate our Buy rating on SLTM."

— William Plovanic, Canaccord Genuity (8/13/12)
more >

"We believe EXAC is undervalued; a full product pipeline should drive continued growth."

— William Plovanic, Canaccord Genuity (8/1/12)
more >

"SLTM is one of the best value picks in medtech."

— William Plovanic, Canaccord Genuity (7/19/12)
more >

"We are projecting EXAC's worldwide hip business to be up 5% YOY."

— William Plovanic, Canaccord Genuity (7/17/12)
more >

Due to permission requirements, not all quotes are shown.